5 reports

OF THESE, ##% OF PATIENTS EXPERIENCE A CHRONIC CONDITION AND ##% OF THESE REQUIRE OPIOIDS FOR PAIN RELIEF.

  • Clinical Trial
  • Ovarian Cancer
  • United States
  • Forecast
  • Nektar Therapeutics

Also additional data showed rapid and sustained pain relief from as early as week ##, which was sustained out to ## years in PsA patients.

  • Clinical Trial
  • Oncology
  • Ovarian Cancer
  • United States
  • GlobalData's company

The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases.

  • Hospital
  • Monoclonal Antibody
  • Ovarian Cancer
  • Therapy
  • Merck & Co., Inc.

Exelixis, Inc. reported interim data on pain relief and related reduction in narcotic analgesic use with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases.

  • Monoclonal Antibody
  • Ovarian Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.

None were unexpected and only one (abdominal pain) was classified as possibly-related to Cvac.

  • Hospital
  • Ovarian Cancer
  • Targeted Therapy
  • Therapy
  • Merck & Co., Inc.